Pulse Biosciences, a pioneering medical technology company focused on the development of its proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology, has announced the appointment of Liane Teplitsky as Chief Operating Officer. The addition of Teplitsky, a seasoned executive with a deep background in cardiac electrophysiology and robotics, marks a significant milestone in the company’s ongoing transition from a broad-based technology developer to a specialized leader in the treatment of atrial fibrillation (AFib). Teplitsky’s arrival follows a series of strategic maneuvers by Pulse Biosciences to streamline its operations and concentrate its capital on the nPulse Cardiac Catheter, a device designed to provide a more precise and safer alternative to traditional thermal ablation methods.
In her new role as COO, Teplitsky will assume oversight of the company’s clinical, regulatory, quality, and commercial functions. This comprehensive mandate places her at the center of Pulse’s efforts to navigate the rigorous regulatory pathways of the United States and Europe. Her appointment is viewed by industry analysts as a tactical move to leverage her extensive experience at major medtech firms, including Abbott and Zimmer Biomet, to accelerate the commercialization of the nPulse platform. Paul LaViolette, CEO of Pulse Biosciences, emphasized that Teplitsky’s leadership will be instrumental as the company executes the pivotal clinical trials required to bring its cardiac ablation solutions to the global market.
A Strategic Pivot Toward Cardiac Care
The appointment of Teplitsky is the latest step in a broader strategic alignment that Pulse Biosciences initiated earlier this year. In March, the company announced a major shift in its Research and Development (R&D) priorities, electing to allocate the vast majority of its resources toward its cardiac applications. This decision necessitated a reduction in spending on other programs, including its surgical clamp program and its percutaneous soft-tissue ablation system. While these technologies showed promise, the company’s leadership determined that the market opportunity and clinical potential of the nPulse Cardiac Catheter represented the most viable path to long-term value creation.
This pivot was largely driven by encouraging first-in-human data collected from 150 patients in Europe. The study demonstrated that Pulse’s nsPFA technology could successfully isolate pulmonary veins with high efficiency and a favorable safety profile. Unlike conventional Pulsed Field Ablation (PFA) systems that operate in the microsecond range, Pulse’s system utilizes nanosecond pulses. This distinction is critical; nanosecond pulses are thought to offer deeper tissue penetration and more localized effects, potentially reducing the risk of collateral damage to surrounding structures such as the esophagus or the phrenic nerve—complications that have long haunted traditional radiofrequency and cryoablation procedures.
The Professional Trajectory of Liane Teplitsky
Teplitsky joins Pulse Biosciences following a successful tenure as the CEO of Artedrone, a startup focused on autonomous robotic technology for the treatment of strokes. Artedrone was recently acquired by Affluent Medical and merged with Caranx Medical to form Carvolix, a move that highlighted Teplitsky’s ability to lead organizations through complex transitions and acquisitions. Her background in robotics is particularly relevant given the increasing integration of robotic assistance in cardiac catheterization labs.
Before her time at Artedrone, Teplitsky served as the President of Global Robotics, Technology, and Data Solutions at Zimmer Biomet. During her tenure there, she was responsible for overseeing the development and deployment of advanced surgical technologies, further honing her expertise in bringing high-tech medical devices to a global audience. However, it is perhaps her decade-long experience at Abbott and St. Jude Medical that most directly informs her new role at Pulse. At these organizations, she held various leadership positions within the cardiovascular and electrophysiology divisions. St. Jude Medical, which Abbott acquired in 2017 for approximately $25 billion, was a dominant force in the AFib market, providing Teplitsky with an insider’s view of the competitive landscape and the clinical requirements for success in the space.
Clinical Milestones and the nPulse Cardiac Catheter
The primary focus of Teplitsky’s initial months at Pulse Biosciences will be the management of the pivotal nPulse Cardiac Catheter trial. The Food and Drug Administration (FDA) granted Investigational Device Exemption (IDE) approval for the trial last year, and the company confirmed that the first patients were enrolled this month. The study is designed to assess the safety and effectiveness of the nPulse system in approximately 215 patients suffering from drug-resistant, symptomatic, paroxysmal atrial fibrillation.
The trial’s primary endpoint is the successful isolation of all targeted pulmonary veins, a standard benchmark in AFib clinical research. By focusing on drug-resistant patients, Pulse is targeting a population with a high unmet need, as current pharmacological treatments often fail to manage the irregular heart rhythms associated with AFib, leading to increased risks of stroke, heart failure, and diminished quality of life.
To support this ambitious clinical program, Pulse has also expanded the role of its Chief Medical Officer, Dr. David Kenigsberg. A practicing electrophysiologist, Dr. Kenigsberg will provide increased leadership capacity, bridging the gap between clinical practice and corporate strategy. This dual-leadership approach, with Teplitsky handling operations and Kenigsberg focusing on clinical excellence, is designed to ensure that the nPulse system is not only regulatory-compliant but also optimized for real-world clinical environments.
Understanding the PFA Market Landscape
The market for atrial fibrillation treatment is undergoing a paradigm shift. For decades, thermal ablation—using either heat (radiofrequency) or extreme cold (cryoballoon)—was the gold standard. However, these methods carry inherent risks of "thermal spread," which can damage non-target tissues. Pulsed Field Ablation has emerged as a disruptive alternative, utilizing electrical fields to create microscopic pores in cell membranes (electroporation), leading to cell death without generating significant heat.
Pulse Biosciences is entering a highly competitive arena. Major incumbents have already made significant strides:
- Boston Scientific: Its Farapulse PFA system was the first to receive FDA approval in early 2024, setting a high bar for adoption.
- Medtronic: Its PulseSelect PFA system also received FDA clearance, leveraging Medtronic’s massive global distribution network.
- Johnson & Johnson (Biosense Webster): The company is advancing its Varipulse platform, integrating it with its widely used Carto mapping system.
Pulse Biosciences seeks to differentiate itself through its "nanosecond" approach. While competitors generally use pulses lasting millionths of a second, Pulse uses pulses lasting billionths of a second. This higher frequency and shorter duration are intended to provide more consistent lesions through thicker heart tissue, potentially reducing the need for "touch-up" ablations—a common requirement in current AFib procedures.
Financial and Operational Context
The restructuring of the executive team, which began with the appointment of Paul LaViolette as CEO and Jon Skinner as CFO earlier in 2023, reflects a stabilization of Pulse’s leadership after a period of turnover. The company has also been active in the capital markets to fund its clinical aspirations. Earlier this year, Pulse completed a rights offering that raised substantial capital, providing the "runway" necessary to complete the pivotal nPulse trial and prepare for potential commercial launch.
The financial commitment to the nPulse program is significant. By cutting investment in the surgical clamp and percutaneous soft-tissue programs, the company has concentrated its burn rate on the highest-probability, highest-impact asset. This "all-in" strategy on PFA is a calculated risk, predicated on the belief that the superior physics of nsPFA will translate into superior clinical outcomes and market share.
Broader Implications for the Medtech Industry
The trajectory of Pulse Biosciences serves as a case study in the modern medtech environment, where specialized innovation often outpaces the broad-spectrum approaches of the past. The appointment of an executive like Teplitsky—who possesses a blend of startup agility and large-cap operational discipline—is a signal to investors that Pulse is preparing for the complexities of a commercial rollout.
If the pivotal trial meets its endpoints, the nPulse Cardiac Catheter could represent a significant advancement in the safety profile of AFib treatments. For patients, this means a lower risk of life-altering complications like atrioesophageal fistula. For hospitals and payers, it could mean shorter procedure times and fewer readmissions, aligning with the broader industry shift toward value-based care.
As the company moves forward under its reinforced leadership team, the focus remains squarely on the data. The results of the 215-patient trial will likely determine the company’s fate in the multi-billion-dollar cardiac ablation market. With Liane Teplitsky at the operational helm, Pulse Biosciences has positioned itself with the requisite expertise to transform its nanosecond technology from a promising laboratory concept into a standard-of-care medical device. The coming 18 to 24 months will be a defining period for the organization as it seeks to validate its technology against the world’s largest medical device manufacturers.